Estrogen receptor status in CHEK2-positive breast cancers: Implications for chemoprevention

Clinical Genetics

Volumn 75, Issue 1, 2009, Pages 72-78

  Cybulski, Cezary ^a   Huzarski, T ^a   Byrski, T ^a   Gronwald, J ^a   Debniak, T ^a   Jakubowska, A ^a   Gorski B ^a   Wokolorczyk D ^a   Masojc B ^a   Narod, S A ^b   Lubinski J ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Centre for Research on Women's Health   (Canada)

Author keywords

Breast cancer; CHEK2; CHK2 gene; Estrogen receptor; Gene

Indexed keywords

CHECKPOINT KINASE 2; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATHOGENESIS; POLAND; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; POLAND; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ESTROGEN; YOUNG ADULT;

EID: 58149193208     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2008.01111.x     Document Type: Article

References (32)

1. CHEK2 Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002: 31: 55-59.
2. Oldenburg RA, Kroeze-Jansema K, Kraan J et al. The CHEK2 1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003: 63: 8153-8157.
3. Vahteristo P, Bartkova J, Eerola H et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002: 71: 432-438.
4. CHEK2 Breast Cancer Case-Control consortium. CHEK2 1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004: 74: 1175-1182.
5. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 2005: 116: 263-266.
6. Shaag A, Walsh T, Renbaum P et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 2005: 14: 555-563.
7. Cybulski C, Wokołorczyk D, Huzarski T et al. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 2007: 102: 119-122.
8. Bogdanova N, Feshchenko S, Cybulski C, Dörk T. CHEK2 mutation and hereditary breast cancer. J Clin Oncol 2007: 25: e26.
9. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: Meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008: 26: 542-548.
10. Zhang S, Phelan CM, Zhang P et al. Frequency of the CHEK2 1100delC mutation among women with breast cancer: An international study. Cancer Res 2008: 68: 2154-2157.
11. Kilpivaara O, Vahteristo P, Falck J et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004: 111: 543-547.
12. Cybulski C, Górski B, Huzarski T et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004: 75: 1131-1135.
13. Cybulski C, Wokołorczyk D, Huzarski T et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 2006: 43: 863-866.
14. Offit K, Pierce H, Kirchhoff T et al. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 2003: 4: 1.
15. Dong X, Wang L, Taniguchi K et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003: 72: 270-280.
16. Bell DW, Kim SH, Godwin AK et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007: 121: 2661-2667.
17. de Bock GH, Schutte M, Krol-Warmerdam EM et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 2004: 41: 731-735.
18. Schmidt MK, Tollenaar RAEM, de Kemp, SR et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 2007: 25: 64-69.
19. Sokolenko AP, Rozanov ME, Mitiushkina NV et al. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 2007: 6: 281-286.
20. Cybulski C, Huzarski T, Górski B et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004: 64: 2677-2679.
21. Walsh T, Casadei S, Coats KH et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006: 295: 1379-1388.
22. Dufault MR, Betz B, Wappenschmidt B et al. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 2004: 110: 320-325.
23. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 2007: 25: 57-63.
24. Honrado E, Osorio A, Palacios J, Benitez J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 2006: 25: 5837-5845.
25. Garcia-Closas M, Hall P, Nevanlinna H et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008: 4: e1000054.
26. Cybulski C, Górski B, Huzarski T et al. CHEK2-positive breast cancers in young Polish women. Clin Cancer Res 2006: 12: 4832-4835.
27. Weischer M, Tybiaerg-Hanson A, Nordestgaard BG. To: Iniesta MD, Merajver SD. CHEK2 screening: Do not think so globally yet. J Clin Oncol 2008: 26: 3092.
28. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: A familial study. Lancet 2005: 366: 1554-1557.
29. Fisher B, Costantino JP, Wickerham DL. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005: 97: 1652-1662.
30. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998: 90: 1371-1388.
31. Narod SA, Lynch HT CHEK2 mutation and hereditary breast cancer. J Clin Oncol 2007: 25: 6-7.
32. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008: 122: 2017-2022.